Vittia (VITT3) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
29 Aug, 2026Executive summary
Net revenue grew 4.2% year-over-year to R$820.0 million in 2025, with strong performance in the Soil Fertilizers segment, which rose 43.2% year-over-year to R$263.6 million.
Adjusted EBITDA reached R$115.2 million, down 13.6% year-over-year, with margin at 14.1% (-2.9 p.p.), the lowest since tracking began.
Adjusted net income was R$60.2 million, a decrease of 20.0% year-over-year; reported profit was higher due to a one-time tax recovery.
Cash generation from operations increased 69.6% to R$110.5 million, supporting a net debt of R$125.6 million and leverage of 1.09x Adjusted EBITDA.
R$50.5 million was returned to shareholders through dividends and share buybacks.
Financial highlights
Net revenue: R$820.0 million in 2025 (+4.2% vs. 2024); Q4 revenue: R$258.1 million (+0.9% vs. Q4 2024).
Adjusted EBITDA: R$115.2 million (-13.6% vs. 2024); margin 14.1% (-2.9 p.p.).
Adjusted net income: R$60.2 million (-20.0% vs. 2024); margin 7.3% (-2.3 p.p.).
Gross profit: R$243.6 million (-8.3% vs. 2024); gross margin: 29.7% (-4.1 p.p.).
Operating cash flow: R$110.5 million (+69.6% vs. 2024).
Net debt: R$125.6 million (-13.4% vs. 2024); net debt/EBITDA: 1.09x.
Outlook and guidance
Management remains confident in medium- and long-term prospects, citing normalization in agribusiness and structural drivers such as sustainability and productivity.
Continued focus on portfolio diversification, operational efficiency, financial discipline, and innovation to capture growth opportunities, with new product launches planned for 2026 and expansion in Mexico.
Expecting only modest growth in 2026, with stabilization of gross margins but no significant price or margin recovery anticipated.
Latest events from Vittia
- Revenue up 37.3% in Q2 2024, but losses persisted as biologicals and investments grew.VITT3
Q2 2024 - Revenue up 6.2% in 3Q24, but profit and margins fell amid drought and market pressure.VITT3
Q3 2024 - Revenue up 4.0% in 2024, net income down 22.6%, with strong biologicals and solid financials.VITT3
Q4 2024 - Revenue up 13.4% year-over-year, but net loss of R$2.0 million and higher net debt.VITT3
Q1 2025 - Revenue up 7% in 1H25, but net loss widened; strong cash flow and new launches support resilience.VITT3
Q2 2025 - Revenue up 5.8% in 9M25, with strong cash flow and innovation amid margin pressure.VITT3
Q3 2025 - Revenue and profitability declined, but net debt fell 19.9% and investment in innovation increased.VITT3
Q1 2026 - Net revenue up 15.1% in 2Q26, strong cash flow, new launches, but EBITDA remains negative.VITT3
Q2 2026